From a technical standpoint, GLP-1 receptor agonists like Ozempic and Wegovy influence the release of insulin, slow gastric emptying, and modulate hunger signals, which in turn affect metabolic parameters
Escribano A, Garcia-Grande A, Montanes P, Miralles L, Garcia A
UHCs 2026 commercial PA criteria for Wegovy require five elements: BMI of 30 or higher, or BMI 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, CVD), documentation of a structured weight management program for at least 6 months in the past 24 months, prescriber attestation that lifestyle changes alone have been inadequate, age 18 or older, and concurrent reduced-calorie diet and physical activity
Included in this kit: FitS36 blends fibers, botanical extracts, spirulina, caffeine, and chromium to support an active routine
Thinking about switching from semaglutide to tirzepatide, or vice versa